Table 3 Characteristics of EC patients with and without prior/concurrent ovarian cancer.

From: Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer

CharacteristicsEC patients - no Ovarian Cancer (N = 1369)aEC patients with Ovarian Cancer (N = 30)cP
bN (%)bN (%)
Endometriosis166 (12.1)13 (43.3)2.1 × 10−4
Leiomyomas799 (58.4)18 (60.0)0.6
Adenomyosis561 (41.0)11 (36.7)0.7
Mean age at EC diagnosis (range)61.5 (26.4–80.0)54.4 (33.3–75.9)5.0 × 10−5
Body Mass Index
<25340 (25.0)7 (23.3) 
25–29.9346 (25.4)9 (30.0) 
≥30676 (49.6)14 (46.7)0.8
Oral Contraceptive use
never448 (32.7)8 (26.7) 
ever920 (67.3)22 (73.3)0.9
Parity
0237 (17.3)10 (33.3) 
1132 (9.6)8 (26.7) 
≥21,000 (73.0)12 (40.0)0.03
Age at Menarche
≤11305 (22.5)9 (30.0) 
12–13651 (48.0)15 (50.0) 
≥14400 (29.5)6 (20.0)0.3
Smoking
never890 (65.1)18 (60.0) 
ever478 (34.9)12 (40.0)0.8
dFamily History of any cancer
no492 (35.9)6 (20.0) 
yes877 (64.1)24 (80.0)0.07
dFamily History of breast cancer
no961 (70.3)14 (46.7) 
yes406 (29.7)16 (53.3)0.003
dFamily History of any Lynch cancer
no665 (48.6)13 (43.3) 
yes704 (51.4)17 (56.7)0.7
eTumor Histology & Grade
Endometrioid Grade 1712 (52.0)13 (43.3)0.3
Endometrioid Grade 2339 (24.8)10 (33.3)0.3
Endometrioid Grade 3119 (8.7)1 (3.3)0.3
Serous (>5%)110 (8.0)1 (3.3)0.3
Clear Cell (>10%), no serous34 (2.5)1 (3.3)0.8
Carcinosarcoma41 (3.0)3 (10.0)0.03
Other epithelial14 (1.0)1 (3.3)0.2
FIGO stage
I1,140 (83.7)16 (53.3) 
II93 (6.8)5 (16.7) 
III107 (7.9)7 (23.3) 
IV22 (1.6)2 (6.7)6.6 × 10−5
Lymphovascular Space Involvement
No/Unknown1081 (79.0)20 (66.7) 
Yes288 (21.0)10 (33.3)0.07
  1. EC, endometrial cancer.
  2. aOvarian cancer was concurrent with EC in 28 patients and prior to EC in 2 patients; Tumor mismatch repair (MMR) status was known for 17 individuals;12 were MMR proficient, 4 were MMR deficient due to MLH1 somatic inactivation (methylation, somatic variant), and 1 MMR deficient individual carried an MLH1 truncating variant considered pathogenic.
  3. bNs may not sum to the total because of missing or unknown data; proportions (%) sum to 100% of observations where data available and excludes missing/unknowns. Ns for endometriosis, leiomyomas and adenomyosis are for each individual condition irrespective of coexistence of either of the other two
  4. cP-values are P-Trend across ordered groups (BMI, Parity, age at menarche, FIGO stage) or logistic regression models for binary variables adjusted for age at EC diagnosis; P-values for tumor histology subtypes are from comparison of proportions.
  5. dCancer reported in at least one first- degree or second-degree relative; Lynch cancers are cancer of the bile duct, bladder, brain, colon/rectum, duodenum, endometrium, gastrointestinal/GI, ovary/fallopian tube, pancreas, renal pelvis, stomach.
  6. eEndometrioid tumor histology and grade were combined into a single variable for Endometrioid Grades 1, 2, or 3; other epithelial include mixed subtypes where serous or clear cell component does not reach % noted, or where the histology was unknown (2 individuals diagnosed by curettage).